Severe manifestations in #COVID19 infection. Dr Fauci #ACR20 @RheumNow Cytokine storm ⚡️⚡️⛈🌩 https://t.co/qsFjjP5iKG

“We remain cautiously optimistic that we will have a safe, effective vaccine based on animal studies.” Here is an up-to-date list of COVID-19 trials as discussed at #ACR20 by Dr. A. Fauci @RheumNow https://t.co/DAoLGGtw1A

Fauci: Common endpoints, common parameters provide "bridge" between #COVID19 vaccine trials. "We are cautiously optimistic" for a vaccine "by the end of the calendar year" because of favorable animal studies, though distribution will be later #ACR20 @Rheumnow. https://t.co/vPLEYiGKam

A reminder or the fundamentals to curbing COVID19 per Dr. Anthony Fauci at #ACR20: 1. Everyone needs to wear a mask 2. Maintain 6 feet distance from others 3. Avoid crowds & congregations 4. Outdoor better than indoors 5. Wash your hands frequently @RheumNow @LCalabreseDO https://t.co/khLS7V2A3b

“If we follow these five fundamentals we will not see the surging (of COVID-19)” Dr. Fauci #ACR20 @RheumNow https://t.co/dcPUmvUdcc

The one time at #ACR20 that only one sceen is on! #LTF @FauciFan @RheumNow so much respect for Dr Fauci! https://t.co/jhvlc8Py7R

Tracking CRP in the hyper-acute phase of admission for #COVID19 predictive of progression to critical illness- suggests trends of inflammatory biomarkers, not absolute admission values, may be most useful for triage & therapy. Abs#0626 #ACR20 @RheumNow https://t.co/E14y3e4ALi

• Early Rise in CRP Is Associated with Progression to Respiratory Failure and Int…

Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB

#COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID pts. Glass is half empty. More hospitalization, ICU, ventilation but death 5% v 4.3%. Abstr#430 #ACR20 @RheumNow @CRASCRRheum https://t.co/cqko0Igd8L

Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors? Can we learn lessons about collaborative work from @rheum_covid? Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy

Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with rheum rx... they haven't read guidelines and may make their own changes! Prepare them for exposure/ifn! #ACR20 @Rheumnow 2F042 https://t.co/HkxbkYjEm3

Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum vs 688 nonrheum. No⬆️risk in rheums after adjusting for race/smoking/comorbidities for: hospitalizations, mech ventil'n 3. ICU 4. death #ACR20 Abstr#L01 @RheumNow https://t.co/362UZUe5dg